@prefix this: . @prefix sub: . @prefix prov: . @prefix dct: . @prefix pav: . @prefix orcid: . @prefix codebase: . @prefix version: . @prefix instance: . @prefix process: . @prefix np: . @prefix rdfs: . @prefix xsd: . @prefix v: . @prefix d: . @prefix dv: . @prefix dr: . @prefix dcat: . @prefix npx: . sub:head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:publicationInfo; a np:Nanopublication . } sub:assertion { d:DB05479 v:identifier "DB05479"; v:namespace "drugbank"; v:uri "http://bio2rdf.org/drugbank:DB05479"; v:x-identifiers.org ; dv:drugbank-id "DB05479"; dv:x-cas ; dv:x-chemspider ; dv:x-pubchemcompound ; dct:description """CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal infections in individuals with compromised immune systems such as those suffering from HIV/AIDS or undergoing organ or bone transplants. The antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. Studies attempting to understand the candidacidal activity of derivatives of alpha-MSH have focused on the alpha-MSH amino acid sequence (6-13), which contains the invariant core sequence His-Phe-Arg-Trp (6-9) that is important for binding to the known melanocortin receptors. A second focus was on the sequence Lys-Pro-Val (11-13) that is known to be important for antimicrobial activity."""@en; dct:identifier "drugbank:DB05479"; dct:title "CZEN 002"@en; a dv:Drug; rdfs:label "CZEN 002 [drugbank:DB05479]"@en; rdfs:seeAlso . } sub:provenance { sub:assertion prov:wasDerivedFrom . dr:bio2rdf.dataset.drugbank.R3 dcat:distribution . dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime; prov:wasDerivedFrom . pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime; prov:wasDerivedFrom . prov:wasAttributedTo . } sub:publicationInfo { sub:signature.MCwCFHc6yv5X8c9H npx:hasPublicKey "MIIBtzCCASwGByqGSM44BAEwggEfAoGBAP1/U4EddRIpUt9KnC7s5Of2EbdSPO9EAMMeP4C2USZpRV1AIlH7WT2NWPq/xfW6MPbLm1Vs14E7gB00b/JmYLdrmVClpJ+f6AR7ECLCT7up1/63xhv4O1fnxqimFQ8E+4P208UewwI1VBNaFpEy9nXzrith1yrv8iIDGZ3RSAHHAhUAl2BQjxUjC8yykrmCouuEC/BYHPUCgYEA9+GghdabPd7LvKtcNrhXuXmUr7v6OuqC+VdMCz0HgmdRWVeOutRZT+ZxBxCBgLRJFnEj6EwoFhO3zwkyjMim4TwWeotUfI0o4KOuHiuzpnWRbqN/C/ohNWLx+2J6ASQ7zKTxvqhRkImog9/hWuWfBpKLZl6Ae1UlZAFMO/7PSSoDgYQAAoGAETGrDm8R3KfndKRj7ttr3jVhhstI6/2Ey0ER9F5kdx7Hrd6eolq7yWzPzf2H754tdZxICzxYcdawBbL2ZUzFjWwXTNUQC3+e6evKPJyNELubnZcA+8TxIIwicBnw3Ku6mSeI8SUVr5SBV1VeJoSu/ahldv562IdBR8IagmzuT3Y="; npx:hasSignature "MCwCFHc6yv5X8c9HLSSbd6SyvZR92AwBAhRIpJqS+KFPL43hAXvKIajmTmL8CQ=="; npx:signedBy instance: . this: dct:created "2018-03-30T11:10:43.509+02:00"^^xsd:dateTime; dct:license ; npx:hasSignatureElement sub:signature.MCwCFHc6yv5X8c9H; prov:wasGeneratedBy process: . instance: prov:specializationOf codebase:; prov:wasAttributedTo orcid:0000-0002-1267-0234 . process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475"; prov:used version:; prov:wasAssociatedWith instance:; prov:wasStartedBy orcid:0000-0002-1267-0234 . version: dct:isVersionOf codebase:; pav:version "eda7951a5f6c622c5d2132f50c3093138484a349"; prov:wasAttributedTo orcid:0000-0002-1267-0234 . }